October 6-7, 2022
Milan, Italy - Cloisters of San Barnaba
Chairs:
Pietro Lampertico and Heiner Wedemeyer
In case of non-receipt of the activation email click here
3.00 - 4.00 pm | Registration, Poster set-up and welcome coffee |
Opening Session | |
4.00 - 4.15 pm | Welcome by Chairs P. Lampertico and H. Wedemeyer |
Session 1 - Virology and Pathogenesis Moderators: M. Dandri and H. Wedemeyer |
|
4.15 - 4.35 pm | The HDV virus: the challenge S. Urban |
4.35 - 4.55 pm | Pathogenesis of HDV: new insights J. Lucifora |
4.55 - 5.15 pm | Immunology of HDV in untreated and treated patients H. Kefalakes |
5.15 - 5.30 pm | Discussion |
Session 2 - Epidemiology and Diagnosis Moderators: F. Caruntu and R. Gish |
|
5.30 - 5.50 pm | Epidemiology of HDV: from low to high endemic countries S. Hamid |
5.50 - 6.10 pm | Epidemiology of HDV in North America: a forgotten disease? N. Reau |
6.10 - 6.30 pm | Diagnosis of HDV: clinical virology and new HBV biomarkers M. Brunetto |
6.30 - 6.45 pm | Discussion |
6.45 - 7.25 pm | KEYNOTE LECTURE From HDV discovery to perspectives of cure Moderators: P. Lampertico and H. Wedemeyer Speaker: M. Rizzetto |
7.25 - 8.15 pm | Apero and DZIF Poster Session |
8.15 - 10.30 pm | Dinner |
8.00 - 8.30 am | Welcome breakfast |
8.30 - 8.45 am | Opening remarks Day 2 P. Lampertico and H. Wedemeyer |
Session 3 - Diagnosis and Natural History Moderators: P. Lampertico and N. Reau |
|
8.45 - 9.05 am | Non-invasive markers of fibrosis in CHD: pros and cons L. Castera |
9.05 - 9.25 am | Natural history of untreated HDV patients: always a progressive disease? S. Aleman |
9.25 - 9.45 am | Endpoints of HDV therapy M. Buti |
9.45 - 10.10 am | Discussion |
10.10 - 10.40 am | Coffee Break and DZIF Poster Session |
Session 4 - Antiviral Treatment I Moderators: M. Cornberg and D. Roulot |
|
10.40 - 11.00 am | Peginterferon therapy: effectiveness, predictors, and long-term outcomes T. Asselah |
11.00 - 11.20 am | Bulevirtide with or without peginterferon alfa: clinical trials H. Wedemeyer |
11.20 - 11.50 am | Bulevirtide with or without peginterferon alfa: real-world studies P. Lampertico |
11.50 - 12.15 am | Discussion |
12.15 - 1.30 pm | Lunch Break and DZIF Poster Session |
Session 5 - Antiviral Treatment II Moderators: K. Agarwal and V. de Lédinghen |
|
1.30 - 1.50 pm | Lonafarnib with or without peginterferon alpha/lambda C. Yurdaydin |
1.50 - 2.10 pm | Anti-HBV drugs targeting HBsAg F. Zoulim |
2.10 - 2.30 pm | Discussion |
Session 6 - Round Table Discussion Moderators: P. Lampertico and H. Wedemeyer |
|
2.30 - 3.45 pm | Hot topics in HDV management. Academia, Pharma and Diagnostics representatives |
- For Academia: S. Aleman, V. de Lédinghen, N. Reau, F. Zoulim - For Pharma and Diagnostics: M. Biermer, I. Choong, G. Cloherty, J.F. Flaherty, C. Hwang, A. Reinhardt, C. Simon |
|
3.45 - 4.00 pm | Closing remarks P. Lampertico and H. Wedemeyer |
Forgot password
Please enter your email address. You will receive a message with the link to reset your password.